EPICS: Global Perspectives in Gastrointestinal Malignancies in 2022 and Beyond
Latest therapeutic developments in GI cancer treatment and implications on individualized clinical decision-making. How will emerging data shape future treatment paradigms?
Faculty Chair
Tanios Bekaii-Saab, MD, FACP
Mayo Clinic Cancer Center, Phoenix, AZ, USA
Faculty Members
Christopher Lieu, MD
University of Colorado Cancer Center, Aurora, CO, USA
Joleen Hubbard, MD
Mayo Clinic, Rochester, MN, USA
Philip A. Philip, MD, PhD
Henry Ford Cancer Institute, Detroit, MI, USA
John H. Strickler, MD
Duke Cancer Center, Durham, NC, USA
Julien Taieb, MD, PhD
University of Paris, France
Gerald Prager, MD, PhD
University of Vienna, Austria
Chiara Cremolini, MD, PhD
University of Pisa, Italy
Alan P. Venook, MD
Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
Scott Kopetz, MD, PhD, FACP
MD Anderson Cancer Center, Houston, TX, USA
Efrat Dotan, MD
Fox Chase Cancer Center, Philadelphia, PA, USA
REPORT TOPICS INCLUDE
- Metastatic Colorectal Cancer – Chemotherapy, Targeted Therapies, and Biomarker-Driven Treatments
- Colorectal Cancer – Immunotherapy
- Hepatocellular Carcinoma
- Gastroesophageal Junction (GEJ) and Gastric Cancer
- Rectal Cancer
- Pancreatic Cancer and Biliary Tract Cancer
